Stocks of BioMarin Pharmaceutical (NASDAQ:BMRN) rallied by 3.4% during the past week but lost 3% on a 4-week basis. The company has outperformed the S&P 500 by 4.64% in the past week but underperformed the index by 3.88% in the last 4 weeks.
BioMarin Pharmaceutical (NASDAQ:BMRN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $84.30 and $82.01 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $84.97. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.86, notching a gain of 3.79% for the day. The total traded volume was 3,994,713 . The stock had closed at $80.80 on the previous day.
The company shares have dropped -40.10% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $151.75 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $85.01 and the 200 Day Moving Average price is recorded at $86.15.
On the companys insider trading activities,The officer (EVP, Chief Financial Officer) of Biomarin Pharmaceutical Inc, Spiegelman Daniel K sold 1,649 shares at $89.14 on June 6, 2016. The Insider selling transaction had a total value worth of $146,992. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN). The shares have now been rated Outperform by the stock experts at the ratings house. The rating by the firm was issued on April 7, 2016. Currently the company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -12.2% . During last six month period, the net percent change held by insiders has seen a change of -3.94%.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).